• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

作者信息

Wing L R, Hawksworth G M, Bennett B, Booth N A

机构信息

Department of Medicine, University of Aberdeen, Scotland.

出版信息

J Lab Clin Med. 1991 Feb;117(2):109-14.

PMID:1899689
Abstract

The role of physiologic inhibitors of tissue-type plasminogen activator (t-PA) in its clearance has not yet been defined. In this study, the clearance of t-PA, plasminogen activator inhibitor 1 (PAI-1), and t-PA-PAI-1 complex was determined in an isolated perfused rat liver system. The clearance of t-PA-PAI-1 complex was twice as fast as that of t-PA, whereas PAI-1 was cleared slowly. The half-lives for t-PA, determined by a two-compartmental pharmacokinetic model, were: alpha, 20.1 minutes, and beta, 120.0 minutes. The corresponding values for t-PA-PAI-1 complex were: alpha, 9.7 minutes, and beta, about 7 hours. The model microconstants were computed for t-PA and t-PA-PAI-1 complex and the marked difference between the "on" microconstants k12 for t-PA (0.026 +/- 0.001 min-1) and t-PA-PAI-1 complex (0.090 +/- 0.025 min-1) suggests that the effect on binding to liver cells is the most important factor in the faster clearance of t-PA-PAI-1 complex when compared with t-PA.

摘要

相似文献

1
Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.
J Lab Clin Med. 1991 Feb;117(2):109-14.
2
Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.组织型纤溶酶原激活剂与1型纤溶酶原激活剂抑制剂复合物与大鼠肝细胞相互作用的表征
Thromb Haemost. 1995 Nov;74(5):1298-304.
3
A kinetic model of the circulatory regulation of tissue plasminogen activator.
Thromb Haemost. 1991 Sep 2;66(3):321-8.
4
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver.组织型纤溶酶原激活剂在三种动物及离体灌注大鼠肝脏中的非线性药代动力学
J Pharmacol Exp Ther. 1990 Oct;255(1):318-24.
5
Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.转化生长因子-β对人视网膜神经胶质细胞中组织型纤溶酶原激活物和纤溶酶原激活物抑制剂-1的调节作用
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2799-805.
6
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。
Thromb Haemost. 1988 Dec 22;60(3):361-4.
7
Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver.
Thromb Haemost. 1996 May;75(5):801-7.
8
Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.纤溶酶原激活物抑制剂1含有一个隐蔽的高亲和力受体结合位点,该位点在与组织型纤溶酶原激活物形成复合物时暴露出来。
Thromb Haemost. 1998 Nov;80(5):822-8.
9
Hepatic clearance of tissue-type plasminogen activator in rats.
Thromb Haemost. 1985 Oct 30;54(3):661-4.
10
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Thromb Haemost. 1989 Sep 29;62(2):651-3.

引用本文的文献

1
Plasminogen Activator Inhibitor-1 and Oncogenesis in the Liver Disease.纤溶酶原激活物抑制剂-1与肝脏疾病中的肿瘤发生
J Cell Signal. 2021;2(3):221-227. doi: 10.33696/signaling.2.054.
2
Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.纤溶酶原激活物抑制剂-1水平升高通过丙型肝炎病毒感染促进癌症干细胞样细胞状态的分化。
J Virol. 2021 Apr 26;95(10). doi: 10.1128/JVI.02057-20. Epub 2021 Feb 24.
3
Metformin, but not glimepiride, improves carotid artery diameter and blood flow in patients with type 2 diabetes mellitus.
二甲双胍而非格列美脲可改善 2 型糖尿病患者颈动脉直径和血流。
Clinics (Sao Paulo). 2012 Jul;67(7):711-7. doi: 10.6061/clinics/2012(07)03.
4
Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism.血浆纤溶酶原激活物抑制剂-1水平升高与登革热死亡风险:与4G/5G启动子多态性无关。
Thromb J. 2005 Nov 7;3:17. doi: 10.1186/1477-9560-3-17.
5
Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.组织型纤溶酶原激活剂突变体与肝细胞的相互作用:结构域缺失的影响。
Biochem J. 1996 Feb 1;313 ( Pt 3)(Pt 3):775-80. doi: 10.1042/bj3130775.
6
Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.纤溶酶原激活物抑制剂在正常肝脏、肝硬化肝脏及有转移的肝脏中的分布。
J Clin Pathol. 1994 Mar;47(3):218-21. doi: 10.1136/jcp.47.3.218.
7
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.肝脏疾病中的组织型纤溶酶原激活剂、纤溶酶原激活剂抑制剂及激活剂-抑制剂复合物
J Clin Pathol. 1994 Mar;47(3):214-7. doi: 10.1136/jcp.47.3.214.
8
Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A.受体相关蛋白水平调节细胞对铜绿假单胞菌外毒素A的敏感性。
Infect Immun. 1995 Aug;63(8):2912-8. doi: 10.1128/iai.63.8.2912-2918.1995.
9
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.组织型纤溶酶原激活物及其丝氨酸蛋白酶抑制剂1型纤溶酶原激活物抑制剂的复合物通过低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体被内化。
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7422-6. doi: 10.1073/pnas.89.16.7422.
10
Characterization of the binding of plasminogen activators to plasma membranes from human liver.纤溶酶原激活剂与人肝细胞膜结合的特性研究
Biochem J. 1992 Nov 1;287 ( Pt 3)(Pt 3):911-5. doi: 10.1042/bj2870911.